The ING2 Knockout Jurkat Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the Jurkat T lymphocyte line, harboring targeted disruptions of the ING2 tumor suppressor gene. This heterogeneous population provides a loss-of-function model for investigating ING2-mediated cellular processes, avoiding clonal artifacts and enabling robust functional studies in an immortalized T cell background.
Jurkat cells are an extensively used immortalized human T cell line originally isolated from the peripheral blood of a patient with acute T cell leukemia. They serve as a standard model for studying T cell receptor signaling, leukemia pathogenesis, and apoptosis, offering rapid growth and a well-characterized signaling landscape. Introducing ING2 knockout in this system allows precise interrogation of tumor suppressor mechanisms relevant to hematological malignancies.
ING2 is a tumor suppressor that functions within the Sin3A-HDAC histone deacetylase complex, directly interacting with Sin3A, HDAC1/2, and SAP30 to modulate chromatin remodeling and gene expression. It is activated by genotoxic stress, p53, and TGF-??, and regulated by the PI3K/AKT pathway. A central mechanism involves ING2-mediated enhancement of p53 acetylation and transcriptional activity, leading to upregulation of the cell cycle inhibitor p21 and the pro-apoptotic factor Bax. ING2 also modulates NF-??B signaling. Representative pathway components include ING2, Sin3A, HDAC1, p53, p21, Bax, ARF, and MDM2, forming a network that integrates DNA damage signals with cell fate decisions.
In the Jurkat T leukemia context, loss of ING2 disrupts tumor suppressive functions, impairing p53-dependent cell cycle arrest and apoptosis. This model is particularly valuable for elucidating how chromatin remodeling defects contribute to T cell leukemogenesis and for evaluating chemosensitivity, as ING2 downregulation is associated with poor prognosis in various cancers. The polyclonal knockout cells may reveal therapeutic vulnerabilities linked to ING2 status.
Research applications span cancer biology, T cell leukemia studies, and p53 pathway analysis. Typical assays include cell viability and proliferation measurements, Annexin V apoptosis detection, cell cycle analysis, western blotting for ING2, p53, acetyl-p53, and p21, RT-qPCR, and co-immunoprecipitation of ING2-Sin3A or ING2-p53 complexes. DNA damage response studies using genotoxic agents further dissect ING2 function. For technical inquiries, please contact Ascent Research.
